-
公开(公告)号：KR102018774B1
公开(公告)日：2019-09-04
申请号：KR1020170028326
申请日：2017-03-06
Applicant: 포항공과대학교 산학협력단 , 연세대학교 산학협력단 , 서울대학교병원
IPC: C12N15/115 , G01N33/574 , G01N33/532 , A61K31/7088
-
公开(公告)号：KR101881500B1
公开(公告)日：2018-07-24
申请号：KR1020160094621
申请日：2016-07-26
Applicant: 주식회사 포스코 , 포항공과대학교 산학협력단
IPC: C12N15/115 , A61K31/711 , G01N33/53
CPC classification number: A61K31/711 , C12N15/115 , G01N33/53
Abstract: 본발명은인슐린수용체에특이적으로결합하는 DNA 압타머, 이를유효성분으로함유하는당뇨병치료용조성물및 당뇨병진단용조성물에관한것으로, 상기압타머는기존의인슐린과다른결합기작을가짐으로써암발병률증가및 죽상동맥경화와같은인슐린에의한부작용보다효과적으로당뇨병을치료하고진단할수 있는것을특징으로한다.
-
Patent Agency Ranking
公开(公告)号：KR1020170013178A
公开(公告)日：2017-02-06
申请号：KR1020160094621
申请日：2016-07-26
Applicant: 주식회사 포스코 , 포항공과대학교 산학협력단
IPC: C12N15/115 , A61K31/711 , G01N33/53
CPC classification number: A61K31/711 , C12N15/115 , G01N33/53
Abstract: 본발명은인슐린수용체에특이적으로결합하는 DNA 압타머, 이를유효성분으로함유하는당뇨병치료용조성물및 당뇨병진단용조성물에관한것으로, 상기압타머는기존의인슐린과다른결합기작을가짐으로써암발병률증가및 죽상동맥경화와같은인슐린에의한부작용보다효과적으로당뇨병을치료하고진단할수 있는것을특징으로한다.
Abstract translation: 本发明涉及特异性结合胰岛素受体的DNA适配体以及包含DNA适体作为活性成分的糖尿病治疗组合物和糖尿病诊断组合物，其中适配体具有与常规胰岛素不同的结合机制，从而 能够有效地治疗和诊断糖尿病，而不会引起胰岛素的副作用，例如动脉粥样硬化和增加的癌症发生率。
-
公开(公告)号：KR101671863B1
公开(公告)日：2016-11-17
申请号：KR1020127028348
申请日：2010-09-15
Applicant: 포항공과대학교 산학협력단 , 주식회사 포스코
IPC: C12N15/115 , C12Q1/68 , A61K48/00 , A61P35/00
CPC classification number: G01N33/57496 , C12N15/115 , C12N2310/16 , C12N2310/335
Abstract: 본발명은뉴클레오린에특이적으로결합하는향상된 G-리치올리고뉴클레오티드(G-rich oligonucleotide) 압타머, 상기압타머의제조방법및 뉴클레오린관련질환을진단및/또는치료하는압타머의용도를제공한다.
-
公开(公告)号：KR1020130012140A
公开(公告)日：2013-02-01
申请号：KR1020130002513
申请日：2013-01-09
Applicant: 포항공과대학교 산학협력단 , 대한민국 (식품의약품안전처장)
IPC: C12N15/115 , A61K48/00 , A61P35/00
Abstract: PURPOSE: A DNA aptamer which specifically binds itself to a breast cancer-related Her2(ERBB2) receptor is provided to effectively suppress metastasis and to diagnose cancer. CONSTITUTION: An ERBB2 aptamer specifically binds itself to ERBB2 and has a base of sequence number 7. The ERBB2 aptamer additionally contains a sequence of sequence number 39 or 40 linked to 5' end and a sequence of sequence number 41 or 42 linked to 3' end. A pharmaceutical composition for treating cancer contains the ERBB2 aptamer as an active ingredient. The cancer includes breast cancer, colon cancer, lung cancer, gallbladder cancer, pancreatic cancer, or gastric cancer. A composition for diagnosing cancer contains the ERBB2 aptamer as an active ingredient.
Abstract translation: 目的：提供特异性结合乳腺癌相关Her2（ERBB2）受体的DNA适体，以有效抑制转移和诊断癌症。 构成：ERBB2适体与ERBB2特异性结合并具有序列号7的碱基。ERBB2适体还包含连接至5'末端的序列号39或40的序列，以及与3'连接的序列号41或42的序列 结束。 用于治疗癌症的药物组合物含有ERBB2适体作为活性成分。 癌症包括乳腺癌，结肠癌，肺癌，胆囊癌，胰腺癌或胃癌。 用于诊断癌症的组合物含有ERBB2适体作为活性成分。
-
公开(公告)号：KR1020130003071A
公开(公告)日：2013-01-09
申请号：KR1020110061939
申请日：2011-06-24
Applicant: 포항공과대학교 산학협력단 , 대한민국 (식품의약품안전처장)
IPC: C12N15/115 , A61K31/7088 , A61P35/00
CPC classification number: C12N15/115 , A61K31/7088 , A61K47/60 , C12N2310/16 , C12N2310/335 , C12N2310/3535 , C12N2320/30 , G01N33/5748 , G01N2333/71 , G01N2333/91205
Abstract: PURPOSE: A DNA aptamer which specifically binds to bread cancer-related Her2(ERBB2) receptor and a composition containing the same are provided to effectively suppress and diagnose cancer. CONSTITUTION: An ERBB2 aptamer specifically binds to ERBB2 and contains 5-15 bases which are substituted with a hydrophobic functional group of a naphthyl group, a benzyl group, a pyrrolbenzyl group, or tryptophane at 5` of dUTP(deoxyuracil). The ERBB2 aptamer contains 40-100 bases including bases selected from sequence numbers 1-35. The ERBB2 aptamer contains 40-100 bases including a base of sequence number 7 or 11. The ERBB2 aptamer additionally contains 15-30 bases at 5` end, 3`end, or both ends of a base sequence selected from sequence numbers 1-35. A pharmaceutical composition for treating cancer contains the ERBB2 aptamer as an active ingredient. A composition for diagnosing cancer contains the ERBB2 aptamer as an active ingredient.
Abstract translation: 目的：提供特异性结合面包癌相关的Her2（ERBB2）受体的DNA适配体和含有该受体的组合物，以有效抑制和诊断癌症。 构成：ERBB2适体与ERBB2特异性结合，并含有5-15个碱基，其在dUTP（脱氧尿嘧啶）5'处被萘基，苄基，吡咯烷基或色氨酸的疏水官能团取代。 ERBB2适体包含40-100个碱基，包括选自序列号1-35的碱基。 ERBB2适体包含40-100个碱基，包括7或11个序列的碱基。ERBB2适体在5'末端，3'末端或两个末端含有15-30个碱基序列，序列号为1-35 。 用于治疗癌症的药物组合物含有ERBB2适体作为活性成分。 用于诊断癌症的组合物含有ERBB2适体作为活性成分。
-
公开(公告)号：KR1020170104398A
公开(公告)日：2017-09-15
申请号：KR1020170028326
申请日：2017-03-06
Applicant: 포항공과대학교 산학협력단
IPC: C12N15/115 , G01N33/574 , G01N33/532 , A61K31/7088
Abstract: 본발명은본 발명은간암관련 Glypican-3 (GPC3)에특이적으로결합하는 DNA 압타머, 이를이용하여글리피칸-3 단백질과관련된암의치료, 이를유효성분으로함유하는암 억제용조성물및 암진단용조성물에관한것이다.
Abstract translation: 发明内容本发明是有关的肝癌磷脂酰肌醇聚糖-3（GPC3）的DNA适体，使用将其绑定到的癌症与蛋白质，含有作为活性成分和癌症诊断此肿瘤抑制该组合物相关联的传递eteuk缩水山核桃-3治疗 ＆lt;
-
-
-
-
-
-
Search Results
17
records
(took 0.033 seconds)
